Choose a language and wait for the translated text.
Shots:
Roche has globally launched the VentanaBAP1 (SP527) test, an automated IHC assay designed to help pathologists identify malignant mesothelioma and distinguish it from other cancers, including NSCLC
Registered as a Class I IVD with the US FDA and approved as a Class C device under IVDR, the assay joins Roche’s MTAP and Claudin-4 tests to improve diagnostic accuracy while preserving limited tissue samples
The combined assays support differential diagnosis and help retain tissue for downstream molecular sequencing and precision medicine testing, addressing a key challenge in lung cancer and mesothelioma diagnostics
Ref: Roche | Image: Roche | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Roche Launches Ventana BAP1 (SP527) Assay to Improve Mesothelioma Diagnosis appeared first on PharmaShots.
